# Metformin and rapamycin Rating: Early — Mostly animal or cell studies; few or uncontrolled human data Type: Compound Updated: 2026-10-15 Canonical: https://heretic.bio/articles/metformin-and-rapamycin.html > Metformin and rapamycin are the best-known pharmaceutical longevity candidates. Rapamycin robustly extends lifespan in mice, including when started late in life, while metformin's case rests on diabetes outcomes and confounded observational data. Neither drug has a completed human lifespan trial, and the definitive metformin trial, TAME, is still not recruiting, so both sit at promising rather than proven. > **Core thesis:** Metformin and rapamycin are the two best-known pharmaceutical geroscience candidates, but they sit in very different evidence buckets. Rapamycin has unusually strong lifespan-extension data across model organisms and genetically heterogeneous mice, while metformin has decades of human safety data and suggestive disease-risk associations. Neither is proven to extend lifespan in healthy humans. * * * ## Evidence at a Glance Intervention | Main Pathway | Strongest Evidence | Human Longevity Evidence | Main Caution ---|---|---|---|--- **Metformin** | Complex I inhibition → AMPK, lower hepatic glucose output, insulin signaling changes | Diabetes outcomes, observational associations, mechanistic geroscience | TAME rationale; no completed definitive aging RCT | GI effects, B12 depletion, exercise-adaptation controversy **Rapamycin / sirolimus** | mTORC1 inhibition, autophagy, protein synthesis restraint, immune remodeling | Robust mouse lifespan extension including late-life start | Small immune/skin/periodontal studies; off-label practice; no definitive lifespan trial | Mouth ulcers, lipids, glucose, wound healing, drug interactions See also [mTOR and AMPK Pathways](mtor-and-ampk-pathways.html), [Autophagy](autophagy.html), [Senolytics](senolytics.html), [NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html), and [Metabolic Health and Insulin](metabolic-health-and-insulin.html). * * * ## Metformin ### Mechanism of Action Metformin is often described as an AMPK activator, but the upstream picture matters: * **Mitochondrial Complex I inhibition** can shift cellular energy state, raising AMP/ATP and activating AMPK-linked programs. * **Hepatic glucose production falls** , improving fasting glucose and insulin exposure in type 2 diabetes. * **Gut effects** may be central: bile-acid signaling, microbiome changes, GLP-1 effects, and intestinal glucose handling. * **Inflammatory and cancer-related signaling** may shift indirectly through insulin, mTOR, NF-κB, and metabolic state. The first-principles interpretation: metformin is not a magic anti-aging molecule; it is a metabolic stressor that can improve an overfed/insulin-resistant terrain. In already insulin-sensitive, highly active people, the benefit-to-noise ratio is less clear. ### Longevity Evidence Important evidence anchors: * **PMID:[27304507](https://pubmed.ncbi.nlm.nih.gov/27304507/)** — Barzilai et al., _Metformin as a Tool to Target Aging_ , outlines the rationale for TAME and aging-as-a-target trial design. * **Observational diabetic cohorts** sometimes show lower cancer/CVD/mortality risks among metformin users, but confounding by indication, immortal-time bias, comparator choice, and diabetes severity are major issues. * **Animal data** are mixed and context-dependent. Some mouse studies show benefit; dose, strain, sex, age at initiation, and diet matter. * **TAME Trial** is conceptually important because it attempts to test a composite of age-related outcomes rather than one disease silo. ### Exercise Interference Debate A recurring concern is that metformin may blunt some exercise adaptations, especially mitochondrial and cardiorespiratory improvements in older adults. This does not mean “never combine metformin and exercise.” It means metformin should not be casually added to a healthy athlete's protocol without a reason such as impaired glucose control. Practical interpretation: * If glucose/insulin markers are poor, metformin may improve the metabolic floor. * If VO₂max, strength, and insulin sensitivity are already excellent, the marginal longevity benefit is unknown. * Training remains a higher-confidence intervention than metformin for most non-diabetic people. ### Uses Strategy | Notes ---|--- Studies started low | Reduces GI intolerance Common metabolic dose | More relevant for diabetes/insulin resistance than speculative longevity Extended release | Often better tolerated Training-sensitive use | Speculative but reasonable if performance is the main goal ### Side Effects and Contraindications * **GI distress:** diarrhea, nausea, cramping; slower titration and ER formulation help. * **Vitamin B12 depletion:** monitor B12, methylmalonic acid, homocysteine if long-term use. * **Renal function:** avoid or use strict medical guidance with severe renal impairment; lactic acidosis is rare but serious. * **Acute illness/surgery/contrast:** temporary holds may be appropriate under clinician guidance. * * * ## Rapamycin / Sirolimus ### Mechanism of Action Rapamycin binds FKBP12 and inhibits **mTORC1** , a nutrient-sensing complex that promotes growth, translation, lipid synthesis, and anabolic signaling. Intermittent mTORC1 inhibition can increase [Autophagy](autophagy.html), reduce some senescence-associated signaling, and shift immune function. Chronic or high exposure may also affect **mTORC2** , which is more associated with insulin resistance and adverse metabolic effects. The central Heretic question is not “is mTOR good or bad?” It is whether timed, partial mTORC1 inhibition can preserve repair and stress resistance without chronically suppressing growth, immune competence, glucose handling, or wound healing. ### Longevity Evidence Rapamycin is the flagship pharmacologic result from the NIA Interventions Testing Program: * **PMID:[19587680](https://pubmed.ncbi.nlm.nih.gov/19587680/)** — Harrison et al. 2009 showed that rapamycin started late in life extended lifespan in genetically heterogeneous mice. * Follow-up ITP studies found sex-, dose-, and protocol-dependent effects. * Benefits have been reported across yeast, worms, flies, and mice, but model-organism conservation does not automatically prove human lifespan extension. * **PMID:[40620657](https://pubmed.ncbi.nlm.nih.gov/40620657/)** reviews the modern longevity debate, off-label use, and translational gaps. ### Human Data: What Exists and What Does Not What exists: * FDA-approved clinical experience with sirolimus/everolimus in transplant and tuberous sclerosis contexts. * Small studies using rapalogs for immune function, vaccine response, dermatologic aging markers, and disease-specific endpoints. * Growing off-label physician experience in longevity clinics. What does **not** exist: * A completed, large, long-duration RCT showing lifespan extension in healthy humans. * Consensus dosing for prevention. * Long-term safety data for decades of intermittent use in healthy people. ### Uses Example Range | Rationale | Main Monitoring ---|---|--- — | Favor mTORC1 pulses, avoid chronic immunosuppression | CBC, CMP, A1c/glucose, fasting insulin, lipids — | Lower side-effect risk; uncertain efficacy | Same, plus symptom tracking — | More pharmacologically continuous; used by some clinicians | More concern for mTORC2/metabolic effects — | Attempts to balance autophagy and recovery | Track wounds, infections, oral ulcers **Do not combine casually** with strong CYP3A4/P-gp inhibitors such as grapefruit, ketoconazole-class antifungals, some macrolides, and certain HIV/HCV drugs. Blood levels can change dramatically. ### Side Effects and Risk Signals * **Mouth ulcers/stomatitis:** common practical limiter. * **Lipids:** LDL/triglycerides may rise. * **Glucose:** insulin resistance or higher glucose can occur, especially with chronic exposure. * **Wound healing:** avoid around surgery, acute injuries, dental procedures, or tissue-repair phases. * **Infection risk:** lower intermittent doses may differ from transplant dosing, but immune effects still require respect. * **Fertility/reproductive signaling:** mTOR is central to growth and reproduction; avoid in pregnancy and when trying to conceive unless medically directed. * * * ## Combined or Sequential Use Some animal studies and longevity clinics discuss combining metformin and rapamycin because they touch nutrient-sensing from different angles: AMPK/insulin and mTOR/autophagy. This is mechanistically plausible but not proven as a healthy-human protocol. Potential logic: 1. Use metformin when the metabolic phenotype is insulin resistant or hyperglycemic. 2. Use rapamycin, if at all, as an intermittent stress-resistance/autophagy signal rather than chronic suppression. 3. Do not stack drugs to compensate for poor sleep, high visceral fat, low muscle mass, or no training. 4. Measure whether the intervention improves the phenotype it was chosen for. * * * ## Natural Mimetics and Adjacent Compounds Per the dietary-restriction-mimetic literature, several natural compounds partly overlap with AMPK/mTOR biology. These are weaker and dirtier than the drugs, but may fit better for low-risk experimentation. Compound | Proposed Overlap | Evidence Caveat ---|---|--- **Berberine** | AMPK/glucose lowering; sometimes compared to metformin | GI effects, drug interactions, variable product quality **Resveratrol** | SIRT1/AMPK signaling; indirect mTOR effects | Human bioavailability and clinical endpoints weak **EGCG** | AMPK and inflammatory signaling | Liver toxicity risk at high supplemental doses **Curcumin** | Inflammatory signaling, AMPK hints | Bioavailability/formulation problems **Spermidine** | Autophagy induction | Human outcomes still developing See [Supplements and Nutraceuticals](supplements-and-nutraceuticals.html) and [NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html). * * * ## Practical Notes ### Baseline Labs Before Considering Either Drug * CBC with differential * CMP including liver enzymes and kidney function * Fasting glucose, fasting insulin, HbA1c * Lipid panel including ApoB if available * hs-CRP * B12, methylmalonic acid, homocysteine for metformin users * Optional: DEXA, VO₂max, grip strength, waist/height ratio, CGM trial ### Decision Heuristics * **Metformin fits best** when insulin resistance, prediabetes, PCOS/metabolic syndrome, or high fasting insulin is present. * **Rapamycin fits, if at all,** as a clinician-supervised experiment in someone with excellent baseline health practices and willingness to monitor labs/side effects. * **Neither substitutes** for resistance training, protein adequacy, sleep regularity, sunlight/circadian alignment, dental health, or visceral-fat reduction. * **Pause rapamycin** around surgery, acute infection, non-healed wounds, or major tissue-repair protocols such as [PRP and Stem Cell Therapies](prp-and-stem-cell-therapies.html) unless a clinician has a specific reason not to. ### Red Flags Requiring Medical Oversight * eGFR <45 for metformin discussion; eGFR <30 generally contraindicated. * Active infection, recurrent mouth ulcers, poor wound healing, uncontrolled lipids/glucose for rapamycin. * Polypharmacy involving CYP3A4/P-gp modulators. * Pregnancy, breastfeeding, fertility treatment, pediatric use. * * * ## Notes * The strongest rapamycin claim is “robustly extends lifespan in mice,” not “proven anti-aging drug in humans.” Keep this distinction explicit. * The strongest metformin claim is “safe, cheap, metabolically useful, and trial-worthy,” not “proven longevity drug for healthy people.” * Need a dedicated note on **rapamycin dosing protocols** if this library expands beyond overview-level treatment. * Track TAME status and any large rapamycin/rapalog prevention trials as they mature. * A major unresolved contradiction: nutrient-sensing inhibition may improve stress resistance while also potentially impairing adaptation, reproduction, wound healing, or athletic gains if mistimed. * * * ## Sources 1. Barzilai N et al. (2016). "Metformin as a Tool to Target Aging." Cell Metabolism . PMID: 27304507 . PMCID: PMC5943638 . (PubMed 27304507, PMC5943638) 2. Harrison DE et al. (2009). "Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice." Nature . PMID: 19587680 . (PubMed 19587680) 3. Roark KM, Iffland PH. (2025). "Rapamycin for Longevity: Pros, Cons, and Future Perspectives." PMID: 40620657 . (PubMed 40620657) 4. Bannister CA et al. (2014). "Can People With Type 2 Diabetes Live Longer Than Those Without?" Diabetes Obesity and Metabolism . PMID: 25059505 . (PubMed 25059505) 5. Gandini S et al. (2014). "Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders." PMID: 24985407 . (PubMed 24985407) 6. Aliper A et al. (2017). "Towards Natural Mimetics of Metformin and Rapamycin." Aging . PMCID: PMC5723685 . (PMC5723685) 7. Kapahi P et al. (2019). "Is Rapamycin a Dietary Restriction Mimetic?" PMID: 30854544 . (PubMed 30854544)